Details for Patent: 12,377,064
Which drugs does patent 12,377,064 protect, and when does it expire?
Patent 12,377,064 protects GIMOTI and is included in one NDA.
This patent has three patent family members in three countries.
Summary for Patent: 12,377,064
| Title: | Treatment of moderate and severe gastroparesis |
| Abstract: | Metoclopramide is administered for the treatment of moderate to severe gastroparesis, in some embodiments, severe gastroparesis. |
| Inventor(s): | Marilyn R. Carlson, Matthew J. D'Onofrio, David A. Gonyer, Wayne Alves |
| Assignee: | Evoke Pharma Inc |
| Application Number: | US18/047,364 |
|
Patent Claim Types: see list of patent claims | Use; Dosage form; |
Drugs Protected by US Patent 12,377,064
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Qol Medcl | GIMOTI | metoclopramide hydrochloride | SPRAY, METERED;NASAL | 209388-001 | Jun 19, 2020 | RX | Yes | Yes | 12,377,064 | ⤷ Start Trial | NASAL ADMINISTRATION OF METOCLOPRAMIDE FOR TREATMENT OF DIABETIC GASTROPARESIS | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,377,064
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Canada | 3047088 | ⤷ Start Trial | |||
| European Patent Office | 3554489 | ⤷ Start Trial | |||
| World Intellectual Property Organization (WIPO) | 2018112061 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
